BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Ashibio Inc readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Ashibio Inc's drugs run\, from Cl
 inicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07024407-6058@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Andecaliximab: Phase 1/2 readout est. (NCT07024407)
DESCRIPTION:Andecaliximab\, phase 1/2.\nStudy: A Study of Andecaliximab in 
 People With Spinal Cord Injury at Risk for Bone Growth Outside of the Norm
 al Skeleton.\nEstimated primary completion: December 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/andecaliximab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07024407
URL:https://assetmemo.bio/drug/andecaliximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06508021-6058@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20290204
DTEND;VALUE=DATE:20290205
SUMMARY:Andecaliximab: Phase 2/3 readout est. (NCT06508021)
DESCRIPTION:Andecaliximab\, phase 2/3\, Fibrodysplasia Ossificans Progressi
 va.\nStudy: A Study of Andecaliximab in Participants With Fibrodysplasia O
 ssificans Progressiva (FOP)\nEstimated primary completion: 4 February 2029
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/andecaliximab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT06508021
URL:https://assetmemo.bio/drug/andecaliximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
